Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123643 · ClinicalTrials.gov registry record · Phase 4
Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients
A Phase 4 study of Type 2 Diabetes Mellitus, sponsored by St. Paul Heart Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT00123643: Completed Phase 4 study of Type 2 Diabetes Mellitus, sponsored by St. Paul Heart Clinic.
NCT00123643 is a Phase 4 study of Type 2 Diabetes Mellitus that has completed, run by St. Paul Heart Clinic. The registered enrollment target is 36 participants, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00123643, a Phase 4 study of Type 2 Diabetes Mellitus, has completed, sponsored by St. Paul Heart Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
Primary Outcome
Measure of endothelial function
Conditions Studied
Interventions
- DRUG rosiglitazone
- DRUG glyburide
Study Locations (1)
Minnesota
- St. Paul Heart Clinic - Saint Paul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2003-05 |
| Est. Completion | 2005-12 |
| Phase | Phase 4 |
What the finished NCT00123643 record still lists
NCT00123643 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 2,960-participant average among 130 other Type 2 Diabetes Mellitus trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which rosiglitazone is the first listed.
NCT00123643 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00123643 about?
NCT00123643 is a clinical study titled "Vascular Effects of Rosiglitazone Versus Glyburide in Type 2 Diabetic Patients". The purpose of this study is to compare the vascular effects of two commonly used diabetes medications, rosiglitazone and glyburide in type 2 diabetic patients.
What is the current status of trial NCT00123643?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2003-05. Estimated completion is 2005-12.
What conditions does trial NCT00123643 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT00123643?
The interventions under investigation include: rosiglitazone (DRUG), glyburide (DRUG).
Who is sponsoring clinical trial NCT00123643?
This trial is sponsored by St. Paul Heart Clinic, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00123643 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00123643's enrollment target sits among peer trials
36 86th of 130 higher than 44 of 130 other Type 2 Diabetes Mellitus trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
ACTIVE NOT RECRUITING · Phase 4
-
Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?
COMPLETED · Phase 4
-
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
COMPLETED · Phase 4
-
Insulin Resistance and Central Nervous System (CNS) Function in Type 2 Diabetes
COMPLETED · Phase 4
-
Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes
COMPLETED · Phase 4
-
Suvorexant on Sleep Disturbance in Patients With Chronic Insomnia and Suboptimally Controlled Type 2 Diabetes
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia